Nutrichem(BJ:833819)2024-04-25 10:07Financial Performance - Revenue for the first quarter of 2024 was ¥1,374,078,857.91, a decrease of 16.35% compared to ¥1,642,558,394.27 in the same period last year[9]. - Net profit attributable to shareholders for the first quarter of 2024 was a loss of ¥29,764,161.30, representing a decline of 142.19% year-over-year[9]. - The company's net profit margin has been negatively impacted by intensified market competition and a slow recovery in the industry[10]. - The company's operating revenue for Q1 2024 was approximately ¥299.05 million, a decrease of 38.2% compared to ¥484.01 million in Q1 2023[45]. - The net profit for Q1 2024 was a loss of approximately ¥31.36 million, compared to a net profit of ¥68.89 million in Q1 2023, representing a significant decline[42]. - The total comprehensive income for Q1 2024 was approximately -¥39.48 million, compared to ¥66.82 million in Q1 2023, reflecting a substantial decrease[43]. - The company's operating profit for Q1 2024 was a loss of approximately ¥32.25 million, compared to a loss of ¥39.47 million in Q1 2023, showing an improvement in operational performance[46]. Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥159,307,829.82, an improvement of 15.07% compared to the previous year's outflow of ¥187,566,831.47[9]. - The cash inflow from operating activities in Q1 2024 was approximately ¥812.07 million, down from ¥1.51 billion in Q1 2023, indicating a decline of 46.2%[48]. - The cash inflow from operating activities in Q1 2024 was 250,648,154.04 CNY, down from 534,855,401.73 CNY in Q1 2023, indicating a decline of approximately 53%[53]. - The net cash flow from operating activities for Q1 2024 was -51,699,136.13 CNY, compared to -90,588,207.73 CNY in Q1 2023, showing an improvement of approximately 43%[54]. - The total cash outflow from operating activities in Q1 2024 was 302,347,290.17 CNY, down from 625,443,609.46 CNY in Q1 2023, marking a reduction of approximately 51.7%[54]. Assets and Liabilities - Total assets as of March 31, 2024, amounted to ¥12,801,345,164.29, reflecting a 1.26% increase from the end of the previous year[9]. - The debt-to-asset ratio for the consolidated entity was 55.08%, up from 54.21% at the end of the previous year[9]. - Total current liabilities increased to CNY 6,045,432,625.60 as of March 31, 2024, compared to CNY 5,933,423,754.04 at the end of 2023, marking a rise of 1.9%[33]. - Non-current liabilities totaled CNY 1,005,598,541.41, an increase of 9.3% from CNY 920,181,127.15 in the previous period[34]. - The total liabilities reached CNY 7,051,031,167.01, up 2.9% from CNY 6,853,604,881.19[34]. Shareholder Information - The total number of ordinary shareholders as of the report date was 26,553[16]. - The largest shareholder, Huabang Life Health Co., Ltd., holds 46.45% of the shares, totaling 569,438,458 shares[19]. - Zhejiang Xin'an Chemical Group Co., Ltd. is the second largest shareholder with 12.31%, holding 150,950,000 shares[19]. - Total shares held by the top ten shareholders account for 70.02% of the company's total shares[20]. - Huabang Life Health Co., Ltd. has pledged 500,000,000 shares, which is a significant portion of its holdings[22]. Investment Activities - Investment activities generated a net cash outflow of ¥165,241,888.51, indicating a significant increase in investment compared to the previous year[11]. - The cash inflow from investment activities in Q1 2024 was 588,596,580.00 CNY, up from 521,405,600.00 CNY in Q1 2023, representing an increase of about 12.9%[54]. - The investment income for Q1 2024 was approximately ¥2.06 million, compared to ¥3.46 million in Q1 2023, reflecting a decrease of 40.4%[46]. Operational Efficiency - Current assets increased to 5,012,768,350.38 yuan from 4,842,717,364.14 yuan, reflecting a growth in liquidity[32]. - Accounts receivable rose to 1,224,109,311.13 yuan, up from 973,466,781.94 yuan, indicating improved sales performance[32]. - Inventory decreased to 1,867,662,749.39 yuan from 1,960,686,648.98 yuan, suggesting better inventory management[32]. - The company's financial expenses in Q1 2024 were approximately ¥26.06 million, down from ¥48.97 million in Q1 2023, indicating a reduction of 46.5%[45]. - The company's interest expenses in Q1 2024 were approximately ¥27.14 million, an increase from ¥24.81 million in Q1 2023, marking a rise of 9.4%[45]. Future Outlook - The company plans to enhance its market expansion efforts and invest in new product development to drive future growth[41].